ea0063p737 | Pituitary and Neuroendocrinology 2 | ECE2019
Bolanowski Marek
, Gu Feng
, Feldt-Rasmussen Ulla
, Zhang Shaoling
, Yu Yerong
, Witek Przemyslaw
, Pedroncelli Alberto M
, Nauwelaerts Heidi
, Jabbour Nadine
, Paul Michaela
, Samson Susan
Background: Pasireotide has proven efficacy in acromegaly and CD, although pasireotide-associated hyperglycaemia occurs in some patients. This Phase IV, randomized, open-label study investigated optimal management of pasireotide-associated hyperglycaemia uncontrolled by metformin/oral antidiabetic therapy (OAD) [NCT02060383].Methods: Adults with acromegaly or CD were enrolled and treated with long-acting pasireotide 40 mg/28 days or subcutaneous pasireot...